Search

Search Constraints

You searched for: Author/Creator Parisi, Sarah

Search Results

1. An increased expression of PI-PLCβ1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes. Issue 5 (14th May 2015)

2. An increased expression of PI‐PLCβ1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes. Issue 5 (14th May 2015)

3. Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia. (30th December 2021)

4. Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment. Issue 4 (5th June 2022)

5. Current therapy and new drugs: a road to personalized treatment of myelodysplastic syndromes. Issue 1 (2nd January 2018)

6. Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML. (11th December 2016)

8. Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents. (28th February 2022)

9. Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant. Issue 4 (7th May 2021)

10. MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia. (7th April 2020)